Apricus Biosciences Inc. (APRI) announced a podium presentation entitled, "Nine months treatment with alprostadil cream (Vitaros) results in sustained improvement of erectile function in males suffering from erectile dysfunction," will take place on August 28, 2012, at 2:30 p.m. CT as part of the upcoming World Meeting on Sexual Medicine or WMSM, which will take place in Chicago, IL, on August 26-30, 2012.
The presentation will discuss the results of a subpopulation analysis of an open label dose titration efficacy and safety study to support Vitaros at the dose of 300 mcg in 100 mg of cream.
On August 16, 2012, Apricus Bio announced that its abstract related to Femprox, its drug candidate in development for female sexual arousal disorder or FSAD, had also been accepted as a podium presentation.
The company said that Vitaros is a topically delivered formulation of alprostadil delivered with Dodecyl 2-N, N-(dimethylamino)-propionate hydrochloride (DDAIP HCl), Apricus' proprietary NexACT delivery technology, for the treatment of erectile dysfunction or ED. When absorbed through the skin, alprostadil, a vasodilator, directly boosts blood flow, thereby causing an erection.
For comments and feedback: editorial@rttnews.com